Search

everythinglearnresearchcommunity

for

Search:↓

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.

Ruxolitinib treatment may cause eyelash growth.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

Photodynamic therapy improved skin issues from sorafenib when other treatments failed.

Older patients with advanced kidney cancer can be managed with a drug called Sunitinib.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Ritlecitinib can help about 14,000 people with severe hair loss.

Gefitinib can cause rare scarring hair loss.

AZD6244 treatment causes skin aging effects by depleting skin stem cells.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Erlotinib can cause hair loss as a side effect.

Ritlecitinib is safe and may effectively treat alopecia areata.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Vemurafenib can cause scalp issues but can be managed without changing the dose.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

Sorafenib often causes skin side effects, indicating effective cancer treatment.

A cancer patient died from a severe skin reaction after taking the drug cetuximab.